RxDoctor Payments Data

Daisy Hoffert, PA

Surgical · Sparks, NVNPI 1275723660

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 24.9% of the total. 2025 is the largest year on record at $1,064, more than ten times the $18 reported in 2021.

$1,523in general payments, 2019–2025

Across 92 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$379
  • Arcutis Biotherapeutics, Inc.$314
  • Novartis$300
  • Incyte Corporation$197
  • Strata Skin Sciences, Inc.$96
  • Lilly USA, LLC$71
  • plus $166 from 6 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie23$379
Arcutis Biotherapeutics, Inc.24$314
Novartis14$300
Incyte Corporation9$197
Strata Skin Sciences, Inc.10$96
Lilly USA, LLC3$71
Sanofi2$46
Johnson & Johnson3$46
UCB, Inc.1$25
Verrica Pharmaceuticals Inc.1$20
Organon1$17
Pfizer1$14

How this compares

$1,523 in reported general payments places this provider in the 70th percentile of 91 surgical providers in Nevada.

See all surgical providers in Nevada

Medicare billing

Part B allowed, 2024
$66,667
Medicare patients
264
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab33$415,346
Skyrizi PenRisankizumab-Rzaa16$326,500
Dupixent PenDupilumab14$52,578
OpzeluraRuxolitinib Phosphate13$25,968
Calcipotriene42$5,251
Clindamycin Phosphate95$4,064
Doxycycline Hyclate80$3,542
Ketoconazole171$3,339
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc116$2,947
Metronidazole44$2,703
Tacrolimus14$1,629
Triamcinolone Acetonide202$1,569
Fluocinonide37$1,453
Fluorouracil17$1,216
Tretinoin29$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$197$25,96813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 91 surgical providers in Nevada.

Other surgical in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →